Skip to main content

Table 1 Patient characteristics and lung function at screening visit

From: Efficacy and safety of nasal high-flow oxygen in COPD patients

 

STIT-1

STIT-2

STIT-1 + 2

Patient demographics

 Sample size (n)

50

27

77

 Sex (male/female)

42/8

15/12

57/20

 Age, years (mean ± SD)

67.2 ± 8.5

64.4 ± 8.2

66.2 ± 8.5

 FEV1 group: 30–50% (n)

31

7

38

 FEV1 group: < 30% (n)

19

20

39

Lung function

 pred. FEV1, % (mean ± SD)

34.5 ± 11.2

24.9 ± 9.2

31.0 ± 11.4

 LTOT, O2 L/min (mean ± SD)

2.2 ± 1.7

2.4 ± 1.4

2.2 ± 1.6

 PaO2, mmHg (mean ± SD)

51.0 ± 6.1

47.0 ± 5.6

49.6 ± 6.2

 PaCO2, mmHg (mean ± SD)

40.0 ± 4.1

49.1 ± 5.4

43.2 ± 6.3

 SpO2 (%)

91 ± 2

89 ± 3

91 ± 2

  1. FEV1: forced expiratory volume in 1 s; LTOT: long term oxygen therapy